INDV Share Price Performance
US$32.16
22.15 (221.28%)
15.0% undervalued intrinsic discount
US$37.86
Fair Value
Price US$32.16
AnalystConsensusTarget US$37.86
AnalystHighTarget US$50.00
Fair ValueUS$37.86
Share Pricen/a
Indivior Pharmaceuticals, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 18 Fair Values set on narratives written by author
INDV Community Narratives
AN
Fair Value US$37.86 15.0% undervalued intrinsic discount
Long Acting Injectable Therapies Will Drive Margin Expansion And Support Long Term Recovery Solutions
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$50 35.7% undervalued intrinsic discount
Long Acting Injectables And Cost Discipline Will Transform This Addiction Treatment Leader
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Long Acting Injectables And Cost Discipline Will Transform This Addiction Treatment Leader
Catalysts About Indivior Indivior focuses on treatments for opioid use disorder, with SUBLOCADE as its lead long acting injectable therapy. What are the underlying business or industry changes driving this perspective?Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$50
35.7% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
3.78% p.a.
Profit Margin
45.21%
Future PE
12.87x
Price in 2029
US$61.34
Long Acting Injectable Therapies Will Drive Margin Expansion And Support Long Term Recovery Solutions
Catalysts About Indivior Indivior develops and commercializes treatments for opioid use disorder with a focus on long-acting injectable therapies. What are the underlying business or industry changes driving this perspective?Read more
28
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$37.86
15.0% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
1.67% p.a.
Profit Margin
38.5%
Future PE
12.17x
Price in 2028
US$46.32
Trending Discussion
Recently Updated Narratives
AN
Long Acting Injectables And Cost Discipline Will Transform This Addiction Treatment Leader
Fair Value: US$50 35.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Long Acting Injectable Therapies Will Drive Margin Expansion And Support Long Term Recovery Solutions
Fair Value: US$37.86 15.0% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Indivior Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- 1.68
- 84.02%
- 16.95%
- -325.5%
About INDV
- Founded
- 2014
- Employees
- 833
- CEO
- WebsiteView website
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company’s core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
